VP3.15

• UNSPSC Description:

  VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS)[1].

• Target Antigen:

  GSK-3; Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease;PI3K/Akt/mTOR;Stem Cell/Wnt

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/vp3-15.html

• Solubility:

  10 mM in DMSO

• Smiles:

  N1(CC/N=C2N=C(C3=CC=CC=C3)N(C4=CC=CC=C4)S/2)CCOCC1

• Molecular Weight:

  366.48

• References & Citations:

  [1]Medina-Rodríguez EM, et al. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep. 2017 Mar 3;7:43545.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1281681-54-6